Antara Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Antara Capital’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-168,939	Closed	-$640K	–	60
2019 Q4	$640K	Buy	+168,939	New	+$809K	0.13%	44

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Antara Capital's ADMS Position: Q1 2020 in Review

Antara Capital sold out of Adamas Pharmaceuticals (ADMS) in Q1 2020, closing a stake of 168,939 shares — an estimated $640K sold.

Antara Capital first reported a position in ADMS in Q4 2019 and held it in 1 quarter. The position peaked at $640K in Q4 2019. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2020.

Antara Capital reported no remaining Adamas Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Antara Capital sold 168,939 Adamas Pharmaceuticals shares in Q1 2020, an estimated $640K.
Antara Capital first reported a position in Adamas Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Antara Capital's Adamas Pharmaceuticals position peaked at $640K in Q4 2019.
73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2020.

Based on Antara Capital's 13F filing for Q1 2020, filed 14 May 2020.